Orion Corporation, Orion Pharma
orion.fiTotal trials
100
Active
3
Phase 3
8
Total enrollment
9,853
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ODM-212 | — | — | — | — | — | 2 | |
| Midazolam | — | — | — | 3 | |||
| Ipilimumab and nivolumab | — | — | — | — | — | 1 | |
| Gemcitabine and nab-paclitaxel | — | — | — | — | — | 1 | |
| sotorasib | — | — | — | — | — | 1 | |
| ODM-208 | — | — | — | — | — | 1 |
Next readouts
- 2026-07-31
- 2027-12-31
- 2029-09
Top conditions
- Asthma21
- Healthy18
- Parkinson's Disease8
- Healthy Volunteers7
- Prostate Cancer5
- Healthy Volunteer Study3
- Amyotrophic Lateral Sclerosis3
- COPD2
Frequently asked questions about Orion Corporation, Orion Pharma
- How many clinical trials does Orion Corporation, Orion Pharma have on ClinicalTrials.gov?
- Orion Corporation, Orion Pharma is listed as the lead sponsor on 100 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Orion Corporation, Orion Pharma's trials are in Phase 3?
- 8 of Orion Corporation, Orion Pharma's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Orion Corporation, Orion Pharma focus on?
- Orion Corporation, Orion Pharma's most-studied conditions on ClinicalTrials.gov are Asthma, Healthy, Parkinson's Disease, Healthy Volunteers, Prostate Cancer.
- When are Orion Corporation, Orion Pharma's next clinical trial readouts?
- Orion Corporation, Orion Pharma has 3 upcoming primary-completion readouts tracked here; the soonest is “Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer”, expected around 2026-07-31.